The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
April 29th 2025
At Asembia’s AXS25 Summit, Shea Hudson spotlighted how pharmacists are transforming into essential clinical partners through advanced technology, patient advocacy, and value-based collaboration.
Split-Dosing Regimen Granted FDA Approval for Multiple Myeloma Treatment
February 12th 2019Daratumumab was first approved in November 2015 as the first and only CD38-directed antibody for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to both.
Read More
Pharmacists Are Happy With Their Salaries, Less So With Their Jobs, Survey Shows (Part 2)
February 12th 2019Although many pharmacists are divided when it comes to their job satisfaction, most of them are currently happy with their compensation, according to a recent Pharmacy Times® Salary and Job Satisfaction Survey.
Read More
Directions in Pharmacy Meetings Announced for Spring 2019
February 8th 2019Pharmacy Times Continuing Education™ (PTCE), a leader in continuing education for retail, health-system, managed care and specialty pharmacists, has announced the ninth annual Directions in Pharmacy® continuing education conference series, which will take place in 4 major cities across the United States in spring 2019.
Read More
Home-Based Monitoring Tests May Boost PrEP Adherence
February 8th 2019To reduce the likelihood of people giving up on PrEP because of difficulty committing to multiple annual visits, a team of investigators created PrEP@Home, a home-based monitoring system that will allow people on the PrEP regimen to meet with their health care providers just once a year, its creators say.
Read More
First Therapy Indicated for Rare Blood Clotting Disorder Granted FDA Approval
February 7th 2019Officials with the FDA have approved caplacizumab-yhdp (Cablivi, Sanofi) injection for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood clotting autoimmune disorder.
Read More
Researchers Link Oxycodone Abuse Deterrent Formulation to HCV Surge
February 6th 2019The 2010 remanufacturing of Purdue Pharma's OxyContin (oxycodone) into an "abuse-deterrent formulation" has been identified as a key contributing factor in opioid abusers switching to heroin injections and the corresponding surge in hepatitis C virus (HCV) infections, according to a new Rand Corporation study.
Read More
CVS Offering Free Heart Health Screenings in February
February 6th 2019Along with providing screenings every Thursday in February, including Valentine’s Day, at MinuteClinlic locations nationwide, CVS has also extended its support to American Heart Association’s Go Red for Women with new $15 million commitment.
Read More